Finally, an orally administered small molecule STAT3 inhibitor Napabucasin, which is currently being tested in several clinical trials against various cancer models (243), have been shown to decrease both STAT3 activation and CD44 expression in biliary tract cancer cells (244). Here, STAT3 is linked to biliary tract cancer.